Three drugmakers will refund covered entities that purchased certain 340B-priced medications following recent adjustments to their 340B drug ceiling prices. [...] …
Category: Regulatory
The Trump administration this month urged a Washington D.C. federal court to uphold a 2013 Health Resources and Services Administration [...] …
A federal judge’s decision to uphold the government’s authority to pre-approve drugmaker 340B rebate models has drawn praise from providers, [...] …
Three drugmakers recently announced refunds for 340B covered entities that were overcharged when buying certain drugs. Viatris, Amgen and GSK [...] …
Breaking News
Federal Judge Upholds HHS’ Right to Pre-Approve 340B Rebates, Tosses Four of Five Drugmaker Lawsuits
A federal district judge has upheld the federal government’s authority to require agency approval of drugmaker 340B rebate models, dealing [...] …
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. provided his first public remarks on the 340B program Wednesday [...] …
Four major drugmakers and an industry vendor are urging a federal judge not to delay ruling on their 340B rebate [...] …
Federal appeals court judges on Friday questioned whether four major insulin manufacturers could have imposed similar 340B contract pharmacy restrictions [...] …
A key national hospital advocacy group recently urged the Trump administration to modify the retrospective payment process under the Inflation [...] …
The U.S. Department of Health and Human Services (HHS) plans to release guidance within 30 days on 340B rebate models [...] …